# Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

> **NCT05513729** · — · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 80 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus With Complication

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT05513729
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-18
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-03-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05513729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05513729, "Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05513729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*